medical cannabis drew visible Canadian participation at Mary Jane Berlin 2026, a four-day event held June 11–14 at Messe Berlin that reported 75,000 visitors and 850 exhibitors. The show combined exhibition halls, outdoor activations, a central stage, and conference programming across several large venues, giving Canadian companies direct access to European buyers, distributors, and consumers.
Major Canadian names appeared in prominent positions. Aurora and Tweed occupied premium booths; Aurora installed a two-story display that included ICAROS virtual-reality fitness systems. Retail chain Canna Cabana presented partner brands such as Tribal and The Loud Plug; its parent company High Tide has recently acquired Remexian Pharma GmbH, a German importer that regularly brings Canadian product into the market.
Smaller producers and regional groups also showed a practical approach to market entry. The Kootenay Collective—represented by Sweetgrass, Kootenay Cultivar, Koots Canna, Kootenay Quantum, Paradise Valley, Rosebud, Leaf Cross and others—built a lounge-style booth with a panoramic Kootenay landscape and grower-specific marketing assets. Dr. Tracey Harvey of Selkirk College, who helped organize the Kootenay presence, said the group aimed to form buyer relationships, coordinate supply, and communicate origin and cultivation practices directly to attendees.
Two measurable factors shaped exhibitor success at the show. First, Germany remains a medical market: patients must hold prescriptions and recreational cannabis has not completed legalization. Second, German marketing rules restrict product presentation and point-of-sale information, so buyers often cannot see grower names or cultivation methods on product packaging. Those two constraints increase the role of importers and distributors who can supply traceability and match producers to German pharmacies and clinics.
Importers used the platform to position Canadian supply. Iuvo’s booth displayed Kootenay Cultivar and Koots Canna and promoted curated storytelling about growers; its founder Jonathan Lubosch-Haenisch highlighted Germany’s 83 million population and described persistent buyer caution about consistent quality. Cantourage took a similar approach outdoors, showcasing JR Strain and Sweetgrass and emphasizing direct connections between cultivators and patients. Cantourage’s marketing director, Patrick Malessa, described Mary Jane as a critical venue to present brands with context and provenance rather than as anonymous catalogue items.
Exhibitor traffic and engagement followed concrete patterns. Location and interactive features correlated with higher booth visits. Large home-grow suppliers and accessory brands—AC Infinity, Vivosun and Puffco—ran the largest installations. Booths offering samples, demonstrations, or visually distinct experiences drew more sustained conversations than static displays. Observers noted many attendees collected promotional items, while buyers concentrated on booths that provided documentation and import pathways.
The event underscored competitive pressures facing Canadian exporters. Large Canadian producers such as Canopy and Aurora can offer scale and standardized product, which supports supply contracts. At the same time, lower-cost producers in countries like Thailand threaten to undercut price-sensitive segments of the market. For regionally focused growers from British Columbia’s Kootenays, competitiveness will depend on two measurable variables: documented quality (lab results, certificates) and reliable logistics (import permits, shelf-stable packaging, distributor agreements).
Canada’s industry position in Berlin reflected changes since legalization at home. Many Canadian operators trimmed costs and refocused after the speculative expansion years. The result: a subset of companies report disciplined margins, reduced overhead, and operational profitability. Those firms can offer predictable supply and compliance documentation—factors German buyers cited as priorities when evaluating foreign product.
Practical next steps for Canadian participants, based on conversations at the event, include: securing German import partners with pharmacy or medical distribution networks; preparing dossier materials that meet German regulatory requests (certificate of analysis, GMP documentation, origin statements); and piloting limited shipments to build a track record for on-time delivery and consistent cannabinoid profiles.
Mary Jane Berlin 2026 did not resolve longer-term questions about scale versus craft. The show confirmed that importers and distributors act as gatekeepers in Germany’s medical market and that provenance-focused groups like the Kootenay Collective must partner with those intermediaries to reach patients. Quantifiable outcomes from the event will appear over the coming months as contracts, sample shipments, and regulatory filings move through import pipelines.
For Canadian growers and brands targeting Europe, the exhibition offered two clear takeaways: German buyers value documented quality and reliable supply chains, and trade shows remain an efficient place to demonstrate both. Companies that can present certificates, stable logistics plans, and verifiable origin stories stand a better chance of converting interest at a crowded expo into repeat orders on German shelves.
Walker Patton, a cannabis strategist and co-founder of the BC Cannabis Alliance, attended with ties to the Kootenay Collective and observed that the strongest market opportunities will accrue to operators who have reduced costs, standardized processes, and can document product consistency. That combination, he noted, aligns with what German medical buyers explicitly requested during the event.
